|
Declaration of interests YYJ reports receiving consulting or advisory board fees from AstraZeneca, Daiichi Sankyo, Imugene, Jounce Therapeutics, Merck Serono, Michael J Hennessy Associates, Paradigm Medical Communications, Pfizer, Seattle, Genetics, and Zymeworks; receiving consulting or advisory and research funding from Eli Lilly, Bristol Myers Squibb, and Merck & Co; receiving research funding from Bayer, Boehringer Ingelheim, Genentech/Roche, MSK Cancer Center Support Grant/Core Grant (P30 CA008748), and Ono Pharmaceutical; receiving speaker's bureau fees from the American Society of Clinical Oncology; and receiving stock options from Rgenix, outside the submitted work. KS reports receiving personal fees for advisory roles from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Ono Pharmaceutical Company, Pfizer, and Takeda; receiving advisory role or research funding from Astellas Pharma, Eli Lilly, Merck Pharmaceutical, and Taiho Pharmaceutical; receiving honoraria (lecture fees) from AbbVie, Novartis, and Yakult Honsha; and receiving research funding from Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, and Medi Science, outside the submitted work. MM reports receiving research grants from AIO, Amgen, German Federal Ministry of Education and Research, Bristol Myers Squibb, European Organisation for Research and Treatment of Cancer, German Cancer Aid, Merck Serono, Merck Sharp & Dohme, and Pfizer; receiving personal fees from Bristol Myers Squibb, Falk Foundation, Lilly, MCI Group, Merck Serono, Merck Sharp & Dohme, Pfizer, and Roche; and receiving non-financial support from AIO, Amgen, Bristol Myers Squibb, German Federal Ministry of Education and Research, European Organisation for Research and Treatment of Cancer, and German Cancer Aid, outside the submitted work. MG reports receiving grants and personal fees from Bristol Myers Squibb and Novartis; and receiving personal fees from Merck Sharp & Dohme and Roche, outside the submitted work. KY reports receiving grants and personal fees from Daiichi-Sankyo, Ono Pharmaceutical Company, Taiho Pharmaceutical, and Yakult Honsha; receiving personal fees from Chugai, Lilly, and Takeda; receiving grants from Sanofi; and receiving personal fees from Bristol Myers Squibb, Merck Serono, and Takeda, outside the submitted work. MS reports receiving personal fees for clinical research from Bristol Myers Squibb, during the conduct of the study; and receiving personal fees for clinical research from Astellas, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, and Roche, outside the submitted work. MT reports receiving research funding from Bristol Myers Squibb, during the conduct of the study. RK reports receiving grants from Amgen, AstraZeneca, Athenex, Eli Lilly, Nektar, and Sanofi; receiving grants and non-financial support from Roche; grants and personal fees from Astellas and Novartis; grants, personal fees, and non-financial support from Bristol Myers Squibb, Merck Sharp & Dohme, and Pfizer; and personal fees from Gador, outside the submitted work. MVK reports serving in an advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, Ipsen, Roche, Sandoz, Sanofi, and Servier, outside the submitted work. RB reports serving as a medical adviser for Merck Serono and Novartis; receiving clinical research funding from Novartis; serving as a medical adviser and speaker for AstraZeneca, Bristol Myers Squibb, and Pfizer; receiving clinical research funding from Bristol Myers Squibb, Merck Sharp & Dohme, and Roche; and serving as a speaker for Merck, during the conduct of the study. TZ reports receiving personal advisory board fees from AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Roche, and Sanofi, outside the submitted work. JMC reports personal fees and consulting and travel support from Bristol Myers Squibb; and research funding from AstraZeneca, Esperas Pharma, Merck, and Tesaro, outside the submitted work. VP, DC, MLe, HX, KK, and MLi report employment with Bristol Myers Squibb and ownership of stock in Bristol Myers Squibb. JAA reports receiving clinical research grants and receiving personal advisory board fees from Bristol Myers Squibb, during the conduct of the study. All other authors declare no competing interests.
|